Shanpar Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 1.60 M
- Paid Up Capital ₹ 1.60 M
- Company Age 13 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.50 M
- Revenue Growth 8.66%
- Profit Growth 22.08%
- Ebitda -4.61%
- Net Worth 41.36%
- Total Assets -5.69%
About Shanpar Pharmachem
Shanpar Pharmachem Private Limited (SPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 17 August 2011 and has a history of 13 years and six months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.60 M and a paid-up capital of Rs 1.60 M.
The company currently has active open charges totaling ₹7.50 M.
Palani Karunakaran and Karunakaran Malarvizhi serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230TN2011PTC081944
- Company No.
081944
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Aug 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Shanpar Pharmachem?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Palani Karunakaran  | Managing Director | 17-Aug-2011 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Karunakaran Malarvizhi | Director | 17-Aug-2011 | Current |
Financial Performance of Shanpar Pharmachem.
Shanpar Pharmachem Private Limited, for the financial year ended 2021, experienced modest growth in revenue, with a 8.66% increase. The company also saw a substantial improvement in profitability, with a 22.08% increase in profit. The company's net worth Soared by an impressive increase of 41.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shanpar Pharmachem?
In 2021, Shanpar Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹7.50 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.75 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Jul 2012 | Axis Bank Limited | ₹7.50 M | Open |
How Many Employees Work at Shanpar Pharmachem?
Unlock and access historical data on people associated with Shanpar Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shanpar Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shanpar Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.